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It is widely accepted that speciﬁc human papillomavirus (HPV) types are the central etiologic agent of cervical carcinogenesis.
However, a number of infected women do not develop invasive lesions, suggesting that other environmental and host factors
may play decisive roles in the persistence of HPV infection and further malignant conversion of cervical epithelium. Although
many previous reports have focused on HPV and environmental factors, the role of host susceptibility to cervical carcinogenesis
is largely unknown. Here, we review the ﬁndings of genetic association studies in cervical carcinogenesis with special reference
to polymorphisms of glutathione-S-transferase (GST) isoforms,p53 codon 72, murine double-minute 2 homolog (MDM2) gene
promoter 309, and FAS gene promoter -670 together with HPV types including our recent research results.
1.Introduction
Cervical cancer is the second most common cancer in
women worldwide, and is both a preventable and a curable
disease especially if identiﬁed at an early stage. It is widely
accepted that speciﬁc human papillomavirus (HPV) types
are the central etiologic agent of cervical carcinogenesis.
Other environmental and host factors also play decisive roles
in the persistence of HPV infection and further malignant
conversion of cervical epithelium [1]. Although many previ-
ous reports have focused on HPV environmental factors, the
role of host susceptibility to cervical carcinogenesis is largely
unknown.
A large number of previous studies have suggested the
possible correlation between genetic polymorphisms of can-
cer susceptibility genes and the higher risk of human malig-
nant tumors [2, 3]. Genetic studies lead to a true association
are expected to increase understanding of the pathogenesis
of each malignancy and to be a powerful tool of prevention
and prognosis in the future. Here, we review the ﬁndings of
genetic polymorphisms of several cancer susceptibility genes
together with HPV types in cervical carcinogenesis based
on our recent research results using exfoliated cervical cell
samples or human cervical squamous carcinoma cell lines.
Our studies were approved by our institutional ethics com-
mittee,andallsampleswereobtainedwithinformedconsent.
To compare the polymorphic features of each genotype and
HPVstatusbetweennormal, LSIL,and HSILgroups, Fisher’s
exact test or Pearson’s chi-square test was used. A level of
P<. 05 was accepted as statistically signiﬁcant.
2.Glutathione-S-TransferaseGSTM1,
GSTT1Polymorphisms
The genes of glutathione-S-transferase (GST) family encode
enzymes that appear to be critical in cellular protection
against the cytotoxic eﬀects. GSTs play an important role in
conjugating glutathione to the products of endogenous lipid
peroxidation and inactivating organic hydroperoxides via
selenium-independent glutathione peroxidase activity, thus2 Pathology Research International
protecting the cell from the deleterious eﬀects of oxidative
stress [4]. GST isoforms GSTM1 and GSTT1 gene deletions
may promote the development of cervical dysplasia by
moderating the activation and detoxiﬁcation of polycyclic
hydrocarbons and other compounds that inﬂuence oxidative
stress and DNA adduct formation [5].
We conductedGST genotype analysis together with HPV
typing in a total of198 cervical smear samples obtained from
the patients who received cervical cancer screening. They
consistof54normal,102low-gradesquamousintraepithelial
lesion (LSIL), and 42 high-grade SIL (HSIL). The protocol
of this study was approved by our institutional review
board, and all samples were obtained from Japanese women
with informed consent. The exfoliated cervical cells were
disrupted with lysis buﬀer, and genomic DNA was extracted
with phenol-chloroform and precipitated with ethanol using
standard techniques. The GSTM1 and GSTT1 genetic poly-
morphisms were evaluated using multiplex PCR techniques
according to the method reported by Chen et al. [6]w i t h
somemodiﬁcationsaspreviouslydescribed[2].Thepresence
ofvarious HPV types was examined by L1-PCR system using
publishedconsensusprimers(L1C1andL1C2)[7] according
to the method reported by Nagano et al. [8].
Figure 1 shows an example for genotyping of GSTM1
and GSTT1. The polymorphic deletion of the GSTM1 and
GSTT1geneswasdeterminedbymultiplexPCR.Theabsence
of 215 or 480bp fragment indicated null GSTM1 or GSTT1
genotype, respectively. Table 1 shows frequency of high-risk
HPV and GSTM1, GSTT1 polymorphisms in 198 exfoliated
cervical cell samples examined. The 42 patients with HSIL
had signiﬁcantly higher frequency of high-risk HPV than
102 with LSIL and 54 controls. There was no signiﬁcant
diﬀerenceinthe frequencyofnull GSTM1 genotypebetween
SILs and controls, whereas the 42 patients with HSIL had
statistically higher frequency of null GSTT1 genotype than
102 with LSIL and 54 controls. As shown in Table 2,t h e3 1
patients with HSIL had also statistically higher frequency
of null GSTT1 genotype than 28 with LSIL among the 69
patients with high-risk HPV.
Previous epidemiological studies of GST and cervical
neoplasia found no signiﬁcant diﬀerencesinthe frequencyof
GSTM1 or GSTT1 in women with SIL or cancer compared
to controls with normal cervical pathology [5, 9, 10]. In
our investigation using exfoliated cervical cell samples from
a Japanese population, the GSTT1 null genotype was more
common among HSIL cases than LSIL cases and controls.
Moreover, the patients with HSIL also had higher frequency
of null GSTT1 genotype than those with LSIL among high-
risk HPV group. GSTT1 diﬀers from other classes of GSTs
in its lack of activity towards the GST model substrate
1-chloro-2,4-dinitrobenzene and its failure to bind to S-
hexyl-glutathione aﬃnity matrices [11]. The gene defect of
GSTT1 was reported to be associated with an increased
risk of myelodysplastic syndromes [12], astrocytoma, and
meningioma [13]. We previously examined GSTM1 and
GSTT1 genotypes in 104 cell lines originating from a variety
of human malignant tumors and found that GSTT1 null
genotype was more common in cervical cancer cells [2].
It might be of interest to further examine the diﬀerence
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Figure 1: Genotyping of GSTM1 and GSTT1 by multiplex PCR.
Lane 1: null GSTM1 genotype (absence of 215bp fragment). Lane
2: null GSTT1 genotype (absence of 480bp fragment). Lane 3:
null GSTM1 and GSTT1 genotypes (absence of 215 and 480bp
fragments). Lane 4: present GSTM1 and GSTT1 genotypes. β-
globin as a positive control is detected as 268bp fragment.
Table 1: Frequency of high-risk HPV and GSTM1, GSTT1
polymorphisms in exfoliated cervical cell samples.
Lesions Number with
high-risk HPV GSTM1null GSTT1 null
Normal (n = 54) 10 (18.5%)a 28 (51.9%) 24 (44.4%)c
LSIL (n = 102) 28 (27.5%)b 55 (53.9%) 40 (39.2%)d
HSIL (n = 42) 31 (73.8%)a,b 20 (47.6%) 29
(69.0%)c,d
aP<. 0001, OR = 12.4 χ2 versus normal. bP<. 0001, OR = 7.4 χ2 versus
LSIL. cP = .0162, OR = 2.8 χ2 versus normal. dP = .0011, OR = 3.5
χ2 versus LSIL.
Table 2: HPV status and frequency of GSTT1 polymorphism in
exfoliated cervical cell samples.
Study group n GSTT1null
High-risk HPV−
Normal 44 20 (45.5%)
LSIL 74 31 (41.9%)
HSIL 11 8 (72.7%)
High-risk HPV+
Normal 10 4 (40.0%)
LSIL 28 9 (32.1%)a
HSIL 31 21 (67.7%)a
aP = .0063, OR = 4.4 χ2 versus LSIL.
in the polymorphic frequency of the null GSTT1 genotype
between SILs and invasive cervical cancer to clarify whether
this genotype alteration occurs prior to the development
of malignant phenotype cells or late in the development of
neoplastic cells.
3.p53 Codon72Polymorphism
p53isatumorsuppressorgeneinvolvedinmultiplepathways
including apoptosis, cellular transcriptional control, and cell
cycle regulation [14, 15]. A large number of human tumors,
including smoke-induced lung cancer, show mutations and
deletions of the p53 gene that result in loss of tumor
suppression function and cell cycle deregulation [16]. A
polymorphism at codon 72 of the p53 gene results in the
substitution of arginine (Arg) for proline (Pro) in the genePathology Research International 3
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Figure 2: Genotyping of p53 codon 72 by PCR-RFLP. Lane 1:
Arg/Arghomozygote.Lane2:Arg/Proheterozygote.Lane3:Pro/Pro
homozygote. The fragment of 199bp is the nondigested PCR
product from the Pro allele.Fragments of113and86bp result from
BstUI digestion of the Arg allele.
Table 3: Frequency of high-risk HPV and p53 codon 72 polymor-
phism in exfoliated cervical cell samples.
Lesions Number with
high-risk HPV
Aminoacid at p53 codon 72
Arg Arg/Pro Pro
Normal
(n = 54) 10 (18.5%)a 24 (44.4%) 23 (42.6%) 7 (13.0%)
LSIL
(n = 102) 28 (27.5%)b 38 (37.3%) 40 (39.2%) 24 (23.5%)
HSIL
(n = 42) 31 (73.8%)a,b 18 (42.9%) 16 (38.1%) 8 (19.0%)
aP<. 0001, OR = 12.4 χ2 versus normal. bP<. 0001, OR = 7.4 χ2 versus
LSIL.
product. It has been suggested that the homozygous Arg
genotypeincreased thesusceptibilityofp53proteintodegra-
dation by E6 protein derived from oncogenic HPV [17].
We conducted genotype analysis of p53 codon 72
together with HPV typing in a total of 198 cervical smear
samples obtained from the patients who received cervical
cancer screening. They consist of 54 normal, 102 LSIL, and
42HSIL,asdescribedabove.PCRrestrictionfragmentlength
polymorphism (RFLP) analysis of codon 72 of the p53 gene,
which was modiﬁed from a technique described by Ara et al.
[18], was conducted to identify p53 genotypes. HPV types
were examined using L1-PCR, as describer above.
As shown in Figure 2, the Arg allele is cleaved by BstUI
and yields two small fragments (113 and 86bp). The Pro
allele is not cleaved by BstUI and has a single 199bp band.
The heterozygote containsthree bands (199,113, and 86bp).
Table 3 shows HPV status and polymorphic frequency of
p53 codon 72 in 198 samples examined. The 42 patients
with HSIL had signiﬁcantly higher frequency of high-risk
HPV than 102 with LSIL and 54 controls, as described
above. The diﬀerences in the polymorphic frequency of p53
Arg, Arg/Pro, and Pro genotypes between SILs and controls
were statistically not signiﬁcant. When the Arg genotype was
compared to the Arg/Pro + Pro genotypes, there was again
no statistical diﬀerence in the genotype prevalence between
SILs and controls with or without high-risk HPV, as shown
in Table 4.
Our present results revealed that the diﬀerences in
the polymorphic frequency of p53 Arg, Arg/Pro, and Pro
Table 4: HPV status andfrequency of p53 codon 72 polymorphism
in exfoliated cervical cell samples.
Study group n Aminoacid at p53 codon 72
Arg Arg/Pro + Pro
High-risk HPV−
Normal 44 20 (45.5%) 24 (54.5%)
LSIL 74 26 (35.1%) 48 (64.9%)
HSIL 11 4 (36.4%) 7 (63.6%)
High-risk HPV+
Normal 10 4 (40.0%) 6 (60.0%)
LSIL 28 12 (42.9%) 16 (57.1%)
HSIL 31 14 (45.2%) 17 (54.8%)
genotypes between SILs and controls were statistically not
signiﬁcant. Moreover, neither Arg nor Pro allele aﬀected
the increased risk of SILs with or without high-risk HPVs
compared to controls. Some previous studies have reported
no correlation between germline polymorphisms of the p53
codon 72 and increased risk of cervical cancer [19–21]. The
other study reported by Nishikawa et al. [22]u s i n gc e r v i c a l
condyloma, dysplasia, and cancer tissue samples demon-
strated that no statistically signiﬁcant diﬀerences in the
distributionofp53genotypeswerefoundamongthepatients
with these diseases, regardless of HPV status. The recent
m e t a - a n a l y s i so np 5 3c o d o n7 2p o l y m o r p h i s mr e p o r t e d
by Klug et al. [23] also demonstrated that no statistically
signiﬁcant diﬀerences in the distribution of p53 genotypes
were found among the patients with cervical diseases. These
data suggest that the p53 codon 72 polymorphism is unlikely
to be associated with the development of HPV-associated
cervical neoplasms.
4.MDM2-SNP309
Murine double-minute 2 homolog (MDM2) is the key nega-
tive regulator of p53, and dysfunction of these genes may be
associated with an increased rate of accumulation of genetic
errors, thereby enhancing the progression of the disease.
A single nucleotide polymorphism (SNP) in the MDM2
gene promoter, SNP309 (a T to G change at nucleotide 309
in the ﬁrst intron), increases the aﬃnity of the promoter
for the transcription activator Sp1, resulting in higher level
of MDM2 mRNA and MDM2 protein and a subsequent
attenuation of the p53 pathway [24]. SNP309 occurs at a
relatively high frequency in the general population and has
been shown to be associated with accelerated tumorigenesis
and the timing of cancer onset [24–27]. However, there have
been very few reports on the correlation between SNP of
MDM2 gene and cervical cancer susceptibility [28].
We conducted genotype analysis of MDM2-SNP309
together with HPV typing in a total of 195 cervical smear
samples obtained from patients with consent who received
cervical cancer screening. They consist of 52 normal,
1 0 2L S I L ,a n d4 1H S I L .E i g h th u m a nc e r v i c a ls q u a m o u s
carcinoma cell lines (SKG-I, SKG-II, SKG-IIIa, SKG-IIIb,
OMC-1, YUMOTO, QG-U, and QG-H) were also used4 Pathology Research International
Table 5: Frequency of high-risk HPV and MDM2-SNP309 in exfoliated cervical cell samples.
Lesions Number with high-risk HPV Genotype frequency Allele frequency
TT TG + GG T G
Normal (n = 52) 10 (19.2%)a 11 (21.2%) 41 (78.8%) 49 (47.2%) 55 (52.8%)
LSIL (n = 102) 28 (27.5%)b 26 (25.4%) 76 (74.6%) 104 (50.6%) 100 (49.4%)
HSIL (n = 41) 30 (73.2%)a,b 7 (17.1%) 34 (82.9%) 37 (45.1%) 45 (54.9%)
aP = .0010 χ2 versus normal. bP = .0019 χ2 versus LSIL.
Table 6: HPV status and frequency of MDM2-SNP309 in exfoliated cervical cell samples.
Study group n Genotype at MDM2-SNP309 OR 95% CI P value
TT TG + GG
High-risk HPV−
Normal 42 8 (18.2%) 36 (81.8%) 1
LSIL 74 14 (18.4%) 60 (81.1%) 0.95 0.36–2.49 .921
HSIL 11 4 (36.7%) 7(63.3%) 0.41 0.10–1.59 .186
High-risk HPV+
Normal 10 3 (30.0%) 7 (70.0%) 1
LSIL 28 12 (42.9%) 16 (57.1%) 0.38 0.10–1.42 .475
HSIL 30 3 (10.0%) 27 (90.0%) 8.88 2.34–33.63 .003
OR: odds ratio.
CI: conﬁdence interval.
for genotype analysis of MDM2-SNP309 together with
H P Vt y p i n g .A l lc e l ll i n e sw e r eoriginating from Japanese
women, as previously described [2]. For MDM2-SNP309
genotyping, two independent PCR assays for each allele,
modiﬁed from a technique described by Menin et al. [25],
were performed using primer pairs speciﬁc for the two
alleles.HPVtypeswere examined using L1-PCR,asdescriber
above.
Figure 3 shows a representative genotyping of MDM-
SNP309 by two independent PCR assays. The wild-type
(T) and the mutant (G) allele yield 121-bp and 168-bp
fragment, respectively. Table 5 shows the frequency of high-
risk HPV and MDM2-SNP309 in 195 exfoliated cervical cell
samples examined. When TT genotype was compared to
TG + GG genotype, 41 patients with HSIL had signiﬁcantly
higher frequency of high-risk HPV than 102 with LSIL and
52 controls; however, there were no statistical signiﬁcant
diﬀerences in the TG + GG genotype prevalence and
allele frequencies between SILs and controls. No statistical
diﬀerence was also found in the genotype frequency of
MDM2-SNP 309 between SILs and controls among 127
patients without high-risk HPV. However, there was an
increased ORforTG+GG genotypein HSILcasescompared
to controls among 68 patients with high-risk HPV, as shown
in Table 6. Interestingly, 21 cases with HPV types 16 and/or
18 had signiﬁcantly higher frequency of the TG + GG
genotype and G allele than 47 with other types of high-risk
HPV, asindicated inTable 7.M or eo v er ,assho wninFigure 4,
genotyping of MDM2-SNP309 in 8 cervical squamous
carcinoma cell lines revealed that TT genotype was detected
only in the SKG-IIIa cell line, whereas the other 7 of 8 (87.5
%) cell lines had TG or GG genotype. In addition, 7 of 8 cell
lines except for YUMOTO were positive for high-risk HPV.
12 34567
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Figure 3: Representative genotyping of MDM2-SNP309 by two
independent PCR assays for each allele. Lanes 1, 5, and 7: TG
heterozygote. Lanes 2, 4, and 6: GG homozygote. Lane 3: TT
homozygote. The wild-type (T) and the mutant (G) allele yields
121-bp and 168-bp fragments, respectively.
Recently, Meissner Rde et al. [28] tested the hypothesis
thatthisfunctional variant intheMDM2promoterwasasso-
ciatedwitheitherriskorearlyagediagnosisofcervicalcancer
in a Brazilian population. A primer-introduced restriction
analysis PCRassay was usedtogenotypetheMDM2-SNP309
of 72 cervical carcinoma patients and 100 healthy women.
However, no statistically signiﬁcant association was observed
between SNP309 and cervical cancer. Moreover, they could
not ﬁnd allele or genotype frequency diﬀerences betweenPathology Research International 5
Table 7: High-risk HPV types and frequency ofMDM2-SNP309 in
exfoliated cervical cell.
Study group
Genotype frequency Allele frequency
TT TG + T G
HPV types
16, 18
(n = 21)
2 (9.5%) 19 (90.5%) 14 (33.3%) 28 (66.7%)b
HPV other
types
(n = 47)
18 (38.2%) 29 (61.8%)a 51 (54.2%) 43 (45.8%)b
aP = .0161 χ2 versus HPV types 16, 18.
bP = .0240 χ2 versus HPV types 16, 18.
the group of patients with cancer diagnosis at an early age
(younger than 40 years old) and the group of older patients.
In contrast, Arvanitis and Spandidos [29]d e m o n s t r a t e d
that MDM2 was one of the potential candidates for the
development of cervical neoplasms. They analyzed the
mRNA expression proﬁles of 24 G1/S checkpoint genes in
cancer and SIL of the uterine cervix. In total 35 squamous
cervicalcarcinomas, 26 HSIL,33 LSIL tissues, and 28 normal
uterine cervix specimens as controls were assessed by RT-
PCR.MDM2wasfoundtobeupregulatedinSIL,whileRBL1
was found to be downregulated in all three groups of cases.
Our present results using exfoliated cervical cell samples
demonstrated that there was an increased OR for TG + GG
genotype in HSIL cases compared to controls among the
patientswith high-risk HPV. We observed that HPV types 16
and 18, the most prevalent and aggressive types worldwide,
are predominant in cases with TG + GG genotype and G
allele. Moreover, 7 of 8 human cervical squamous carcinoma
cell lines that possess high-risk HPV except YUMOTO also
showed TG or GG genotype. These observations suggest
that MDM2-SNP309 and high-risk HPV infection may
be cooperatively associated with cervical carcinogenesis. It
would be of interest to further evaluate whether MDM2-
SNP309 has the potential to be used in conjunction with
HPV-DNAtesting and cervical cytologyfor the management
of SIL patients.
5.FasGene Promoter-670 Polymorphism
Apoptosis is a physiological process that regulates normal
homeostasis, and alterations of apoptosis-related genes are
likely to contribute to the pathogenesis of autoimmune
diseases [30] and malignant tumors [31]. Among various
cell surface death receptors, Fas/CD95, a transmembrane
receptor, is known as a member of tumor necrosis factor
(TNF) receptors superfamily [32]. Downregulation of Fas
with resultant resistance to death signals has been reported
in many cancers [33–35]. The transcriptional expression of
Fasgeneisregulated bya number ofgeneticelementslocated
in the 5  upstream promoter region of the gene. SNP at -670
in the enhancer region (A/G) situates at a binding element
of gamma interferon activation signal (GAS). Homozygous
for G allele could result in a complete deletion of the binding
sequence of transcription element GAS, which is responsible
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Figure 4: Genotyping of MDM2-SNP309 in 8 cervical squamous
carcinoma cell lines by two independent PCR assays for each allele.
The TT genotype was detected only for SKG-IIIa, whereas the TG
genotype for SKG-I, SKG-II, SKG-IIIb, and OMC-1, and the GG
genotype for YUMOTO, QG-U, and QG-H cell lines, respectively.
AA GA GG
44bp
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Figure 5: Genotyping of Fas gene promoter -670 in DNA samples
from peripheral blood lymphocytes by PCR-RFLP. The genotypes
AA (232bp), GA (189, 233bp), and GG (189bp) are shown.
for the signal emanated through STAT1, and in a signiﬁcant
alteration in the gene expression [36, 37]. However, the
correlation between this SNP and cancer susceptibility
includingtheriskofgynecologicalmalignancieshasnotbeen
extensively studied.
We conducted genotype analysis of Fas gene promoter
-670 together with HPV typing in a total of 279 cervical
smear samples obtained from the patients with consent who
receivedcervicalcancerscreening.Theyconsistof63normal,
1 6 7L S I L ,a n d4 9H S I L .E i g h th u m a nc e r v i c a ls q u a m o u s
carcinoma cell lines (SKG-I, SKG-II, SKG-IIIa, SKG-IIIb,
OMC-1, YUMOTO, QG-U, and QG-H) were also used for
genotype analysis of this SNP together with HPV typing,
as described above. PCR-RFLP analysis of the Fas gene
promoter -670, modiﬁed from a technique described by Lee
et al. [38], was conducted, and HPV types were examined
using L1-PCR, as describer above.
Figure 5 shows an example for genotyping of Fas gene
promoter -670 in exfoliated cervical cell samples. The
fragments of 232 and 188bps indicated the AA and GG6 Pathology Research International
Table 8: Frequency of high-risk HPV and Fas promoter -670 polymorphism in exfoliated cervical cell samples.
Lesions Number with high-risk HPV Genotype frequency Allele frequency
AA GA + GG A G
Normal (n = 63) 10 (15.9%)a 19 (30.2%) 44 (69.8%)c 67 (53.2%) 59 (46.8%)e
LSIL (n = 167) 46 (27.5%)b 51 (30.5%) 116 (69.5%)d 165 (49.4%) 169 (50.6%)f
HSIL 40 (81.6%)a,b 5 (10.2%) 44 (89.8%)c,d 37 (37.8%) 61 (62.2%)e,f
aP<. 0001χ2 versus normal, bP<. 0001χ2 versus LSIL,
cP = .0107 χ2 versus normal, dP = .0043χ2 versus LSIL,
eP = .0217χ2 versus normal, fP = .0422χ2 versus LSIL.
Table 9: HPV status and frequency of Fas promoter -670 polymorphism in exfoliated cervical cell samples.
Study group n Genotype at Fas promoter -670 OR 95% CI Pf
AA GA + GG
High-risk HPV−
Normal 53 15 (28.3%) 38 (71.7%) 1
LSIL 121 36 (29.8%) 85 (70.2%) 0.93 0.44–1.95 .847
HSIL 9 1 (11.1%) 8 (88.9%) 3.16 0.40–25.04 .276
High-risk HPV+
Normal 10 4 (40.0%) 6 (60.0%) 1
LSIL 46 15 (32.6%) 31 (67.4%) 1.38 0.34–5.66 .655
HSIL 40 4 (10.0%) 36 (90.0%) 6.00 1.32–27.37 .021
OR: odds ratio.
CI: conﬁdence interval.
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Figure 6: Genotyping of Fas gene promoter -670 in 8 cervical
squamous carcinoma cell lines by PCR-RFLP. The AA genotype
was detected only for QG-U, whereas the GA genotype for SKG-
I, OMC-1, and YUMOTO, and the GG genotype for SKG-II, SKG-
IIIa, SKG-IIIb, and QG-H cell lines, respectively.
genotypes, respectively. The GA genotype contained these
two bands. Table 8 shows the frequency of high-risk HPV
and Fas promoter -670 polymorphism in 279 samples
examined. When AA genotype was compared to GA + GG
genotype, 49 patients with HSIL had signiﬁcantly higher
frequencyofhigh-risk HPVandGA +GGgenotypethan167
with LSIL and 63 controls. G allele frequency was also higher
in HSIL than in LSIL and controls. There was no statistical
diﬀerenceintheGA + GG genotypeprevalencebetweenSILs
and controls among 183 patients without high-risk HPV as
shown in Table 9. However, there was an increased odds ratio
(OR) for GA + GG genotype in HSIL cases compared to
controls among 96 patients with high-risk HPV. As shown in
Figure 6, genotyping of Fas gene promoter -670 in 8 cervical
squamous carcinoma cell lines revealed that AA genotype
was detected only in the QG-U cell line, whereas the other
7 of 8 (87.5 %) cell lines had GA or GG genotype.
Polymorphisms in the promoter region or 5  ﬂanking
region of genes can lead to diﬀerent levels of gene expression
and have been also implicated in a number of diseases.
Recently, Lai et al. [39] conducted Fas promoter -670
polymorphism analysis usingsurgicalandbiopsytissuespec-
imens of cervical neoplasm and reported that the frequency
of A allele and AA genotype increased in accordance with
the multistep carcinogenesis from LSIL, HSIL to invasive
squamous cell cancer. They stated that A allele and AA geno-
type, conferring an intact GAS element and more eﬃcient
Fas expression, could be one of the mechanism that cells
use to avoid carcinogenesis. In contrast, our present results
using exfoliated cervical cell samples demonstrated that the
frequency of GA + GG genotype or G allele increased from
LSIL to HSIL. Moreover, there was an increased OR for GA
+ GG genotype in HSIL cases compared to controls among
the patients with high-risk HPV. Recently, Engelmark et al.
[40]a n dD y b i k o w s k ae ta l .[ 41]h a v ed e m o n s t r a t e dt h a tA A
g e n o t y p ei nF a sg e n ep r o m o t e ra t-670 position may not be
engaged in the development of cervical neoplasia in Swedish
and Polish population, respectively. These discrepancies may
be due to the ethnic variation of genotype frequency of Fas
gene promoter in diﬀerent geographical regions.
Previous studies [42, 43] have demonstrated that high-
risk HPV infection is inversely correlated with apoptosis of
cervical epithelial cells and that a decrease of apoptosis is
closely associated with higher histologic grade of SIL. In
cervical cancer tissues and cell lines, signiﬁcant decrease in
the expression levels of Fas has been also reported [43, 44].
The higher frequency of GA or GG genotype in HSIL cases
in our series may result in a signiﬁcant decrease in FasPathology Research International 7
gene expression and subsequent escape from apoptosis of
the cells in high-risk HPV-related cervical carcinogenesis.
Interestingly, 7 of8 human cervicalsquamous carcinoma cell
lines that possess high-risk HPV except for YUMOTO also
showed GA or GG genotype. Fas gene promoter polymor-
phism may be closely associated with cervical carcinogenesis
particularly in high-risk HPV group. These observations are
potentially important in managing SIL patients by cytologic
examination and in understanding the pathogenesis of
cervical cancer.
6.Conclusionand FutureDirections
Here, we review the ﬁndings of genetic association studies
in cervical carcinogenesis with special reference to polymor-
phisms of GST isoforms, p53 codon 72, MDM2-SNP309,
and FAS gene promoter -670 together with HPV types
including our recent research results. Our studies using
exfoliated cervical cell samples or human cervical squamous
carcinoma cell lines have demonstrated that the GSTT1
null genotype, the TG/GG genotype of MDM2-SNP309,
and the GA/GG genotype or G allele of Fas promoter -670
are closely associated with cervical carcinogenesis together
with high-risk HPV infection. It would be of interest to
further evaluate whether these polymorphisms could be
used as a disease marker for the natural history of cervical
neoplasms in a setting of longitudinal cohort study and
for the determination of appropriate screening interval in
patients with or without high-risk HPV.
HPV are the etiologicagentsofcervical and otherepithe-
lial cancers. Persistence of infections by high-risk HPV types
is the single greatest risk factor for malignant progression.
Vaccination against HPV types 16 and 18 has commenced or
will soon commence in a number of countries. Our studies
have demonstrated that the frequency of G allele increased
from LSIL to HSIL and that there was an increased OR for
G allele in HSIL cases with high-risk HPV types including 52
and 58. It is known that geographically diﬀerent oncogenic
HPV types 52 and 58 are more prevalent than 16 and 18 in
East Asia. HPV prevalence should be considered and treated
individually regarding the strategy that best suits the HPV
types in a given geographical area. It is likely that novel
strategies in combination with vaccination against HPV
types 16 and 18 are required in those countries where other
types of HPV may be more prevalent. Moreover, further
studies on the diﬀerential gene expression proﬁles between
normal cervical keratinocytes and cervical cancer cell lines
may provide the better understanding for the eﬀect of these
polymorphisms in the sequence of cervical carcinogenesis.
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